Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “JAK2 Mutation”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)Study completedNCT04243122
What this trial is testing

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Who this might be right for
Myeloproliferative Neoplasm (MPN)Essential Thrombocythemia (ET)JAK2 Mutation+3 more
Ottawa Hospital Research Institute 44
Testing effectiveness (Phase 2)Study completedNCT00586651
What this trial is testing

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Who this might be right for
Polycythemia VeraEssential Thrombocytosis
Cephalon 39
Very early researchEnded earlyNCT03272633
What this trial is testing

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia in RemissionHematopoietic Cell Transplantation Recipient+16 more
Rutgers, The State University of New Jersey 2
Early research (Phase 1)Not Yet RecruitingNCT07249840
What this trial is testing

Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

Who this might be right for
JAK2 Mutation
Brigham and Women's Hospital 12
Large-scale testing (Phase 3)Active Not RecruitingNCT06514807
What this trial is testing

Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Who this might be right for
Essential Thrombocythaemia
AOP Orphan Pharmaceuticals AG 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04517851
What this trial is testing

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Who this might be right for
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
M.D. Anderson Cancer Center 15
Not applicableStudy completedNCT01352585
What this trial is testing

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

Who this might be right for
Essential Thrombocythemia (ET)
Shire 47
Not applicableNot Yet RecruitingNCT07108023
What this trial is testing

Hematological Disorders in EHPVO Patients

Who this might be right for
Extrahepatic Portal Vein Obstruction (EHPVO)ThrombophiliaMyeloproliferative Neoplasms (MPN)+5 more
Rahab Nady 115
Not applicableLooking for participantsNCT06480591
What this trial is testing

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Who this might be right for
Myeloproliferative Neoplasm
Wake Forest University Health Sciences 35
Not applicableLooking for participantsNCT05123326
What this trial is testing

Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome

Who this might be right for
Hepatic Vein ThrombosesHepatic Venous Outflow ObstructionPortal Vein Thrombosis+7 more
Post Graduate Institute of Medical Education and Research, Chandigarh 300
Very early researchEnded earlyNCT03972943
What this trial is testing

CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Who this might be right for
CALR Gene MutationEssential ThrombocythemiaJAK2 Gene Mutation+3 more
University of Utah 8
Testing effectiveness (Phase 2)Looking for participantsNCT03801434
What this trial is testing

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Who this might be right for
BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+9 more
William Shomali 10
Testing effectiveness (Phase 2)Study completedNCT02311569
What this trial is testing

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Who this might be right for
Myeloproliferative NeoplasmPrimary MyelofibrosisEssential Thrombocythemia+1 more
Swiss Cancer Institute 39
Not applicableStudy completedNCT04667988
What this trial is testing

JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

Who this might be right for
Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
Mansoura University 76
Not applicableUnknownNCT04527666
What this trial is testing

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Who this might be right for
Gastroesophageal VaricesJAK2 MutationMyeloproliferative Neoplasm
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)UnknownNCT00668421
What this trial is testing

CEP-701 (Lestaurtinib) in Myelofibrosis

Who this might be right for
MyelofibrosisEssential ThrombocythemiaPolycythemia Vera
Ronald Hoffman 60
Not applicableUnknownNCT04525768
What this trial is testing

Gastroesophageal Varices in Cavernoma

Who this might be right for
Gastroesophageal VaricesMyeloproliferative NeoplasmPortal Caver Cavernoma+1 more
Shanghai Zhongshan Hospital 80
Testing effectiveness (Phase 2)WithdrawnNCT04354727
What this trial is testing

APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Who this might be right for
Myelofibrosis
Ascentage Pharma Group Inc.
Not applicableStudy completedNCT03828422
What this trial is testing

Arterial Function and Atherosclerosis in Essential Thrombocythemia

Who this might be right for
Atherosclerosis
University Medical Centre Ljubljana 82